Affinity Asset Advisors, LLC Summit Therapeutics Inc. Transaction History
Affinity Asset Advisors, LLC
- $896 Million
- Q1 2025
A detailed history of Affinity Asset Advisors, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 140,000 shares of SMMT stock, worth $2.77 Million. This represents 0.53% of its overall portfolio holdings.
Number of Shares
140,000Holding current value
$2.77 Million% of portfolio
0.53%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding SMMT
# of Institutions
236Shares Held
86.8MCall Options Held
1.84MPut Options Held
3.13M-
Baker Bros. Advisors LP New York, NY24.4MShares$484 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$231 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$157 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$130 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$96.2 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.99B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...